TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04727671

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin acetate
Description: 0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix
Description: 0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Description: Dosage adjustment according to the ovarian response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Description: Dosage adjustment according to the ovarian response.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Chorionic Gonadotropin (hCG)
Description: Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Chorionic Gonadotropin (hCG)
Description: Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm.
Study: NCT06117514

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sudapyridine 30mg
Description: Sudapyridine capsule 30mg, orally, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sudapyridine 100mg SAD
Description: Sudapyridine tablet, 100mg orally, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sudapyridine 200mg SAD
Description: Sudapyridine tablet, 200mg orally, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sudapyridine 200mg MAD
Description: Sudapyridine tablet, 200mg orally once a day for 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sudapyridine 300mg MAD
Description: Sudapyridine tablet, 300mg orally once a day for 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet SAD
Description: Placebo tablet, 100mg orally, single dose
Study: NCT01666977

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 6
Study: NCT04085016

Intervention type: DEVICE
Intervention: Keratograph 5M, Oculus, Wetzlar, Germany

Intervention type: DEVICE
Intervention: Keratograph 5M, Oculus, Wetzlar, Germany
Study: NCT03014362

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuronetics NeuroStar XPLOR magnetic stimulator - Active
Description: Localization: Left prefrontal dorsolateral neocortex. Dose Delivery: Figure-8 solid core coil at 120% motor threshold, 10 Hz, 4 second train duration, 10 second interval for 30 minutes.~Treatment Dose: \~4k/session, 12-15k/day, 36-45k total pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neuronetics NeuroStar XPLOR magnetic stimulator - Sham
Description: Localization: Left prefrontal dorsolateral neocortex. Sham Delivery: Figure-8 solid core coil rendered inert via blocking insert. Dose: Zero pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC.
Study: NCT00408226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MKC-1
Description: capsules, twice daily for 14 days in 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: standard dosing of 500 mg/m2 infused every 21 days
Study: NCT03784495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 1mg
Description: 1 mg/day 30 minutes before sleep

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential Aminoacids (eAA)
Description: 4g/day of Essential Aminoacids during breakfast. Packets of powdered amino acid supplements (42.0% leucine, 14.0% lysine, 10.5% valine, 10.5% isoleucine, 10.5% threonine, 7.0% phenylalanine, and 5.5% other) were provided for the participants to be taken with water or milk, and they were instructed to take the 4-gram supplement once a day every day for 4 weeks.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Essential Aminoacids + melatonin
Description: 4g/day of Essential Aminoacids during breakfast + 1 mg/day of Melatonin 30 minutes before sleep. Packets of powdered amino acid supplements (42.0% leucine, 14.0% lysine, 10.5% valine, 10.5% isoleucine, 10.5% threonine, 7.0% phenylalanine, and 5.5% other) were provided for the participants to be taken with water or milk, and they were instructed to take the 4-gram supplement once a day every day for 4 weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: an isocaloric amount of maltodextrin with the same flavor and appearance as the intervention product
Study: NCT03661918

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: In-Person First Session
Description: Conduct first session in person vs. over the phone

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: In-Person First Session
Description: Conduct first session in person vs. over the phone

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: In-Person First Session
Description: Conduct first session in person vs. over the phone

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: In-Person First Session
Description: Conduct first session in person vs. over the phone

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Second Caregiver
Description: Have second caregiver participate in three coaching calls

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Second Caregiver
Description: Have second caregiver participate in three coaching calls

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Second Caregiver
Description: Have second caregiver participate in three coaching calls
Study: NCT06117514

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 200mg SAD
Description: Placebo tablet, 200mg orally, single dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet MAD
Description: Placebo tablet, 200mg orally once a day for 14 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet MAD
Description: Placebo tablet, 300mg orally once a day for 14 days
Study: NCT02725502

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: Baseline HbA1C will be assessed. Before starting treatment with linagliptin or placebo Mixed meal test will be conducted with the standard protocol. Morning dose of insulin to be omitted on the day of mixed meal test. During the mixed meal test glucose, C-peptide, GLP1 and glucagon will be measured at 0, 30, 60, 120, 180 minutes. 72 hour blood glucose profile to be monitored with continuous glucose monitoring system (CGMS). Markers of glucose control and glucose variability will be measured. Then we will randomly divide these patients in two group (linagliptin and placebo group). After 3 month period 72 hour blood glucose profile, HbA1C and Mixed meal test will be repeated to document any change in blood glucose profile.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Baseline HbA1C will be assessed. Before starting treatment with linagliptin or placebo. Mixed meal test will be conducted with the standard protocol. Morning dose of insulin to be omitted on the day of mixed meal test. During the mixed meal test glucose, C-peptide, GLP-1 and glucagon will be measured at 0, 30, 60, 120, 180 minutes. 72 hour blood glucose profile to be monitored with CGMS. Markers of glucose control and glucose variability will be measured. Then we will randomly divide these patients in two group (linagliptin and placebo group). After 3 month period 72 hour blood glucose profile, HbA1C and Mixed meal test will be repeated to document any change in blood glucose profile.
Study: NCT02302495

Intervention type: DRUG
Group type: OTHER
Intervention: Carfilzomib
Description: DOSING REGIMEN.~The regimen will have 2 parts:~Part 1. Induction. Nine 5 weeks cycles (35-days each) of weekly Carfilzomib Melphalan Prednisone are planned Carfilzomib. 36, 45, 56 or 70 mg/m² on days 1, 8, 15, 22 IV route followed by a 13-day rest period per 35-days cycle. Patients will start the first cycle day 1 with 20mg/m².~In combination with oral Melphalan 0.25mg/kg/j and oral prednisone 60mg/m², both on days 1 to 4.~Part 2. Maintenance. Carfilzomib. 36 mg/m² weekly, every two weeks IV route for 1 year. Melphalan and Prednisone is not pursued at this phase of the study.
Study: NCT02351115

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A=Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A=Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A=Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A=Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A=Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B=Inhaled Alprazolam 0.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B=Inhaled Alprazolam 0.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B=Inhaled Alprazolam 0.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B=Inhaled Alprazolam 0.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B=Inhaled Alprazolam 0.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C=Inhaled Alprazolam 1 m

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C=Inhaled Alprazolam 1 m

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C=Inhaled Alprazolam 1 m

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C=Inhaled Alprazolam 1 m

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C=Inhaled Alprazolam 1 m

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D= Inhaled Alprazolam 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D= Inhaled Alprazolam 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D= Inhaled Alprazolam 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D= Inhaled Alprazolam 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D= Inhaled Alprazolam 2 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E=Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E=Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E=Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E=Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E=Placebo
Study: NCT01053312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] Flutemetamol
Description: All subjects will receive an intravenous (IV) dose of \[18F\]flutemetamol (less than 10µg flutemetamol). The nominal activity of a single administration of \[18F\]flutemetamol will be 185 megabecquerels (MBq).
Study: NCT01818544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-8501
Description: BAY85-8501 (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning
Study: NCT02281812

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: After tumor ablation and excision of the tumor, the pathologist performed a macroscopic study of the specimen,measuring the distance between the tumor and the margin in order to indicate if extensions are mandatory. Secondly and delayed, margins will be evaluated microscopically by H\&E stain. Furthermore, the tumoral viability in the ablation zone will be evaluated by NADH-diaphorase, COX and tunnel.
Study: NCT01021943

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: spironolactone
Description: Half of the subjects will be assigned to receive 25 mg of spironolactone for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Half of the subjects will be assigned to receive placebo for 6 months
Study: NCT00860470

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Iron (27 mg) - folic acid (600 ug)
Description: Supplement serves as the Control (providing the current standard of care during pregnancy). Mothers instructed to take 1 tablet per day, from the 1st trimester through 12 weeks post-partum.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient
Description: Containing 15 micronutrients all at an RDA including: vitamin A (770 ug retinol equivalents, vitamin D (5 ug), vitamin E (15 mg), folic acid (600 ug), thiamin (1.4 mg), riboflavin (1.4 mg), niacin (18 mg), vitamin B-12 (2.6 mg), vitamin B-6 (1.9 mg), vitamin C (85 mg), iron (27 mg), zinc (12 mg), iodine (220 ug), copper (1000 ug), selenium (60 ug).~Mothers instructed to take 1 tablet per day, from the 1st trimester through 12 weeks post-partum.
Study: NCT01549990

Intervention type: DRUG
Intervention: Sevoflurane
Description: maintenance of general anesthesia with sevoflurane

Intervention type: DRUG
Intervention: desflurane
Description: maintenance of general anesthesia with desflurane
Study: NCT03058484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Health Worker intervention
Description: The intervention included four integrated components: 1) formal linkage of CHWs to health facilities; 2) CHW-led antiretroviral therapy (ART) adherence counseling; 3) loss to follow-up tracing by CHWs; and 4) distribution of Action Birth Cards (ABCs), a birth planning tool.
Study: NCT03935971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: See arm/group description
Study: NCT03268798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Unilateral wrist extension training
Description: Participants will join a five-week training protocol with 3 sessions per week. During each session, 5 sets 5 maximal wrist extension training will be performed on participants less affected side.
Study: NCT00650923

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ziv-aflibercept
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo RT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT03661918

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Second Caregiver
Description: Have second caregiver participate in three coaching calls
Study: NCT03653676

Intervention type: OTHER
Intervention: Exercise Test (CIIT)
Description: The CIIT exercise test will consist of 8 bouts (2 minute each) of constant workload cycling with rest periods (1 minute each) in between each bout of exercise. Subjects and controls will be randomized to either a moderate intensity or vigorous intensity, defined as 50% or 70% of the maximal workload achieved on the maximal cardiopulmonary exercise test (CPET).

Intervention type: OTHER
Intervention: Exercise Test (CIIT)
Description: The CIIT exercise test will consist of 8 bouts (2 minute each) of constant workload cycling with rest periods (1 minute each) in between each bout of exercise. Subjects and controls will be randomized to either a moderate intensity or vigorous intensity, defined as 50% or 70% of the maximal workload achieved on the maximal cardiopulmonary exercise test (CPET).
Study: NCT04023422

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinical intervention
Description: The community health navigator will ask patient to produce medications, to indicate if there are current smokers in the home, to look for structural problems within the home, presence of pests, allergens, pollutants. Pt will be asked to produce their current medications. At the end a report will be written for the clinician.
Study: NCT03869268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor will be allocated as a single loading dose of 180 mg (2 x 90 mg orodispersible tablets) and will be used in conjunction with aspirin depending on the arm of the trial the participant is randomised to.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor will be allocated as a single loading dose of 180 mg (2 x 90 mg orodispersible tablets) and will be used in conjunction with aspirin depending on the arm of the trial the participant is randomised to.
Study: NCT03869268

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor will be allocated as a single loading dose of 180 mg (2 x 90 mg orodispersible tablets) and will be used in conjunction with aspirin depending on the arm of the trial the participant is randomised to.
Study: NCT03894176

Intervention type: OTHER
Intervention: Plasma PTX3 concentration
Description: Long pentraxin 3, thrombus burden, final TIMI flow, ST segment resolution, STEMI, primary PCI
Study: NCT02879149

Intervention type: DEVICE
Intervention: AUGMENT® Bone Graft
Description: AUGMENT® Bone Graft

Intervention type: PROCEDURE
Intervention: Standard of Care
Description: Autologous Bone Graft
Study: NCT04531631

Intervention type: DRUG
Group type: OTHER
Intervention: Dorzagliatin
Description: tablet
Study: NCT03661918

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WiFi-enabled Scale
Description: Have participant weigh in weekly on a wifi-enabled scaled vs. regular scale

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WiFi-enabled Scale
Description: Have participant weigh in weekly on a wifi-enabled scaled vs. regular scale

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WiFi-enabled Scale
Description: Have participant weigh in weekly on a wifi-enabled scaled vs. regular scale
Study: NCT01218867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose in 5% water (D5W) with mesna 15 mg/kg/day X 2 days over 1 hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose in 5% water (D5W) with mesna 15 mg/kg/day X 2 days over 1 hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose in 5% water (D5W) with mesna 15 mg/kg/day X 2 days over 1 hr
Study: NCT03661918

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WiFi-enabled Scale
Description: Have participant weigh in weekly on a wifi-enabled scaled vs. regular scale
Study: NCT04531631

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: placebo

Intervention type: DRUG
Group type: OTHER
Intervention: placebo
Description: placebo
Study: NCT01218867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose in 5% water (D5W) with mesna 15 mg/kg/day X 2 days over 1 hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose in 5% water (D5W) with mesna 15 mg/kg/day X 2 days over 1 hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose in 5% water (D5W) with mesna 15 mg/kg/day X 2 days over 1 hr

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg (Arms 1-7) or 72,000 IU/kg (Arms 8-11) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg (Arms 1-7) or 72,000 IU/kg (Arms 8-11) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg (Arms 1-7) or 72,000 IU/kg (Arms 8-11) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg (Arms 1-7) or 72,000 IU/kg (Arms 8-11) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg (Arms 1-7) or 72,000 IU/kg (Arms 8-11) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
Study: NCT03638843

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric mucosal devitalization
Description: Gastric mucosal devitalization is an endoscopic procedure which uses argon plasma coagulation to result in selective damage to the gastric mucosa and submucosa.
Study: NCT02694718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine is available as 50 mg and 500 mg tablets. It will be administered as a 1000mg/m\^2 bid orally on Days 1-14, and at a dose of 825mg/m\^2 bid on Days 22-35 and 43-56.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin is available in vials containing 50 mg or 100 mg. It will be administered as a oxaliplatin 130mg/m\^2/d intravenously on Day 1 and 50mg/m\^2/d on Days 22, 29, 43 and 50 prior to radiotherapy up to Week 9 followed by surgery period.
Study: NCT01218867

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg (Arms 1-7) or 72,000 IU/kg (Arms 8-11) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)